Context:
-
With assistance from ICMR, Panacea Biotec has developed India’s first domestic dengue vaccine, and more than 8,000 people have signed up for Phase 3 trials.
-
What Is the First Dengue Vaccine in India?
-
DengiAll is a tetravalent dengue vaccine that offers protection against all four serotypes of the dengue virus (DENV-1 to DENV-4).
-
Origin: Based on the TV003/TV005 strain that was first created by the National Institutes of Health (NIH) in the United States and licensed to Indian companies.
-
The Indian Council of Medical Research (ICMR) is the main sponsor and scientific leader of the project.
-
Leading formulation trials and possessing process patents, Panacea Biotec is a vaccine developer.
-
-
How Does It Operate?
-
-
Nature of tetravalents: lowers the risk of reinfection by providing immunity against all four dengue strains.
-
Weakened viruses are introduced by live-attenuated viruses to safely elicit an immune reaction.
-
Two-dose vaccination: After receiving doses, participants undergo a two-year medical follow-up to evaluate the vaccine’s effectiveness.
-
-
Important attributes:
-
-
All of India Coverage: Twenty locations, including Chennai, Pune, Delhi, and Hyderabad, are hosting trials.
-
Large-scale Participation: Of the 10,000 targeted candidates, nearly 80% of them completed the enrolment process.
-
Process Patented: Panacea is the owner of the exclusive rights to the vaccine’s creation.
-
Prior Trial Success: Phases 1 and 2 were finished in 2018–19 with positive outcomes.
-
Clinical Vigilance: After vaccination, participants will be observed for two years.
-
-
Importance to India:
-
-
Impact on Public Health: Deals with one of the most common diseases spread by mosquitoes in India.
-
Child Health Focus: Provides vital protection for kids, who are more likely to need hospitalisation.
-
Because there is little cross-protection between dengue serotypes, it is essential to reduce recurrent infections.
-
